Literature DB >> 29202622

An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG).

Anne-Vibeke Laenkholm1, Dorthe Grabau2, Maj-Lis Møller Talman3, Eva Balslev4, Anne Marie Bak Jylling5, Tomasz Piotr Tabor6, Morten Johansen7, Anja Brügmann8, Giedrius Lelkaitis3, Tina Di Caterino9, Henrik Mygind1, Thomas Poulsen10, Henrik Mertz11, Gorm Søndergaard12, Birgitte Bruun Rasmussen4.   

Abstract

INTRODUCTION: In 2011, the St. Gallen Consensus Conference introduced the use of pathology to define the intrinsic breast cancer subtypes by application of immunohistochemical (IHC) surrogate markers ER, PR, HER2 and Ki67 with a specified Ki67 cutoff (>14%) for luminal B-like definition. Reports concerning impaired reproducibility of Ki67 estimation and threshold inconsistency led to the initiation of this quality assurance study (2013-2015). The aim of the study was to investigate inter-observer variation for Ki67 estimation in malignant breast tumors by two different quantification methods (assessment method and count method) including measure of agreement between methods.
MATERIAL AND METHODS: Fourteen experienced breast pathologists from 12 pathology departments evaluated 118 slides from a consecutive series of malignant breast tumors. The staining interpretation was performed according to both the Danish and Swedish guidelines. Reproducibility was quantified by intra-class correlation coefficient (ICC) and Lights Kappa with dichotomization of observations at the larger than (>) 20% threshold. The agreement between observations by the two quantification methods was evaluated by Bland-Altman plot.
RESULTS: For the fourteen raters the median ranged from 20% to 40% by the assessment method and from 22.5% to 36.5% by the count method. Light's Kappa was 0.664 for observation by the assessment method and 0.649 by the count method. The ICC was 0.82 (95% CI: 0.77-0.86) by the assessment method vs. 0.84 (95% CI: 0.80-0.87) by the count method.
CONCLUSION: Although the study in general showed a moderate to good inter-observer agreement according to both ICC and Lights Kappa, still major discrepancies were identified in especially the mid-range of observations. Consequently, for now Ki67 estimation is not implemented in the DBCG treatment algorithm.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29202622     DOI: 10.1080/0284186X.2017.1404127

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  8 in total

1.  Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium.

Authors:  Gábor Cserni
Journal:  Virchows Arch       Date:  2018-03-28       Impact factor: 4.064

2.  Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.

Authors:  Garazi Serna; Sara Simonetti; Roberta Fasani; Francesca Pagliuca; Xavier Guardia; Paqui Gallego; Jose Jimenez; Vicente Peg; Cristina Saura; Serenella Eppenberger-Castori; Santiago Ramon Y Cajal; Luigi Terracciano; Paolo Nuciforo
Journal:  Breast       Date:  2020-07-13       Impact factor: 4.380

3.  Optoacoustic imaging of the breast: correlation with histopathology and histopathologic biomarkers.

Authors:  Gisela L G Menezes; Ritse M Mann; Carla Meeuwis; Bob Bisschops; Jeroen Veltman; Philip T Lavin; Marc J van de Vijver; Ruud M Pijnappel
Journal:  Eur Radiol       Date:  2019-05-27       Impact factor: 5.315

4.  Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method.

Authors:  Junmei Hao; Yan Lyu; Jiarui Zou; Yunyun Zhang; Shuishan Xie; Lili Jing; Fangrong Tang; Jiahong Lyu; Wenfeng Zhang; Jianbo Zhang; Xunting Wang; Kuisheng Chen; Jiandi Zhang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

5.  Visual and digital assessment of Ki-67 in breast cancer tissue - a comparison of methods.

Authors:  Anette H Skjervold; Henrik Sahlin Pettersen; Marit Valla; Signe Opdahl; Anna M Bofin
Journal:  Diagn Pathol       Date:  2022-05-06       Impact factor: 3.196

6.  Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience.

Authors:  Nikolaos A Trikalinos; Deyali Chatterjee; Jane Lee; Jingxia Liu; Greg Williams; William Hawkins; Chet Hammill
Journal:  Ann Surg Oncol       Date:  2020-03-23       Impact factor: 4.339

7.  Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.

Authors:  Lorenza Mittempergher; Leonie Jmj Delahaye; Anke T Witteveen; Mireille Hj Snel; Sammy Mee; Bob Y Chan; Christa Dreezen; Naomi Besseling; Ernest Jt Luiten
Journal:  Transl Oncol       Date:  2020-03-21       Impact factor: 4.243

8.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.

Authors:  Torsten O Nielsen; Samuel C Y Leung; David L Rimm; Andrew Dodson; Balazs Acs; Sunil Badve; Carsten Denkert; Matthew J Ellis; Susan Fineberg; Margaret Flowers; Hans H Kreipe; Anne-Vibeke Laenkholm; Hongchao Pan; Frédérique M Penault-Llorca; Mei-Yin Polley; Roberto Salgado; Ian E Smith; Tomoharu Sugie; John M S Bartlett; Lisa M McShane; Mitch Dowsett; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2021-07-01       Impact factor: 13.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.